Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00527046 · ClinicalTrials.gov registry record · Phase 2
Effects Of An Oral Growth Hormone Secretagogue In Older Functionally Limited Adults
A Phase 2 study, sponsored by Pfizer.
- Terminated
- Registry status
- Phase 2
- Development phase
- 396
- Enrollment target
NCT00527046: Clinical Trial Phase 2 study, sponsored by Pfizer.
NCT00527046 is a Phase 2 study that was terminated before completion, run by Pfizer. The registered enrollment target is 396 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (198% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00527046, a Phase 2 study, was terminated before completion, sponsored by Pfizer.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 396 participants
- Enrollment target
Study Summary
A 24-month, placebo controlled, double dummy, parallel-design outpatient trial in generally healthy elderly men and women who are at risk of becoming frail.
Interventions
- DRUG CP-424,391
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 396 participants |
| Start Date | 1999-12 |
| Est. Completion | 2001-10 |
| Phase | Phase 2 |
Why NCT00527046 stopped before completion
NCT00527046 is an interventional study that assigns participants to a tested intervention. The registered 396 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (198% higher).
The record links to 0 conditions, and to 1 intervention - of which CP-424,391 is the first listed.
NCT00527046 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00527046 about?
NCT00527046 is a clinical study titled "Effects Of An Oral Growth Hormone Secretagogue In Older Functionally Limited Adults". A 24-month, placebo controlled, double dummy, parallel-design outpatient trial in generally healthy elderly men and women who are at risk of becoming frail.
What is the current status of trial NCT00527046?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 396 participants. The study started on 1999-12. Estimated completion is 2001-10.
What interventions are being tested in trial NCT00527046?
The interventions under investigation include: CP-424,391 (DRUG).
Who is sponsoring clinical trial NCT00527046?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00527046's enrollment target sits among peer trials
396 103rd of 2000 higher than 1,898 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05633615 · 396 participants · Phase 2
Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
- NCT06227910 · 396 participants · Phase 3
A Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Disease
- NCT06545331 · 396 participants · Phase 1
Study of XB010 in Subjects With Solid Tumors
- NCT06666790 · 396 participants · NA
DermaSensor Postmarket Surveillance Study
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia